Your browser doesn't support javascript.
loading
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel, Anisha B; Farooq, Sahira; Welborn, Macartney; Amaria, Rodabe N; Chon, Susan Y; Diab, Adi; Glitza Oliva, Isabella C; Huen, Auris O; Li, Shirley Q; Nelson, Kelly C; Pacha, Omar; Patel, Sapna P; Rapini, Ronald P; Tawbi, Hussein A; Wong, Michael K; McQuade, Jennifer; Davies, Michael A; Haydu, Lauren E.
Afiliación
  • Patel AB; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Farooq S; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.
  • Welborn M; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.
  • Amaria RN; Department of Dermatology, University of Florida, Gainesville, Florida.
  • Chon SY; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Diab A; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Glitza Oliva IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huen AO; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li SQ; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nelson KC; Baylor College of Medicine, Houston, Texas.
  • Pacha O; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patel SP; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.
  • Rapini RP; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wong MK; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McQuade J; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haydu LE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 128(5): 975-983, 2022 03 01.
Article en En | MEDLINE | ID: mdl-34724197
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Neoplasias Cutáneas / Inmunoterapia / Melanoma Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Neoplasias Cutáneas / Inmunoterapia / Melanoma Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article